Galapagos | L'Utile Ante Imposte

Q3Q32024Q3

	Pre Tax Profit	Cambiamento		Data
argenx SE	USD 88.02M		103.02M	2024-09
AstraZeneca	USD 1.67B		162M	2024-12
Biogen	USD 572.2M		118.5M	2024-12
Genmab	DKK 3.6B		1.88B	2024-12
Gilead Sciences	USD 2.96B		112M	2024-12
GlaxoSmithKline	GBP 563M		2.08B	2024-12
GRIFOLS	EUR 66.98M		38.41M	2024-06
Hikma Pharmaceutical	USD 144M		144M	2024-06
Incyte	USD 406.83M		147.12M	2024-12
Merck	EUR 1.23B		449.38M	2024-09
Neurocrine Biosciences	USD 162.6M		27.7M	2024-12
Novartis	USD 4.66B		269M	2024-12
Roche Holding	CHF 1.78B		2.33B	2024-12
Sanofi	EUR 2.18B		1.33B	2024-12
UCB	EUR 123M		464.07M	2024-06
Vertex Pharmaceuticals	USD 1.32B		109.7M	2024-12

Galapagos L'Utile Ante Imposte - Valori correnti, dati storici, previsioni, statistiche, grafici e calendario economico - Mar 2025.